A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)

A Multicenter, Randomized, Double-blind Phase Ш Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)

The main purpose of this study is to evaluate the efficacy and safety in patients with advanced breast cancer treated with SYHX2011 versus paclitaxel for injection (albumin-bound).

Study Overview

• Status: Not yet recruiting
• Conditions: Advanced Breast Cancer
• Intervention / Treatment: Drug: SYHX2011; Drug: Paclitaxel for injection (albumin-bound)

• Study Type: Interventional
• Enrollment (Anticipated): 454
• Phase: Phase 3

Contacts and Locations

Study Locations

• China
  • Hebei
    • Shijia Zhuang, Hebei, China
      • The Fourth Hospital of Hebei Medical University
      • Contact: Cuizhi Geng; Phone Number: 86-0311-66696233; Email: hb4thgcp@126.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Voluntarily sign the written informed consent.

2. Breast cancer confirmed by histology or cytology and meeting the following conditions:

   1. According to the breast cancer diagnosis and treatment guidelines (2022) of the Chinese Society of Clinical Oncology (CSCO), the investigators judge the breast cancer patients who are suitable for anti-tumor treatment with paclitaxel for injection (albumin-bound) alone.
   2. According to RECIST 1.1 standard, there is at least one measurable focus. For the lesions that have been treated with radiotherapy in the past, the lesions can be included in the measurable lesions only if the disease progression is clear after radiotherapy.
3. Age ≥ 18 years.
4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 within 7 days before the first administration.
5. Expected survival time ≥3 months.

6. Normal function of main organs within 7 days before the first administration [no blood transfusion, erythropoietin (EPO), granulocyte colony stimulating factor (G-CSF) or other medical support treatment within 14 days before the first administration], meeting the following criteria:

   1. Absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L; Platelet count (PLT)≥ 100 × 10^9/L; Hemoglobin (Hb) ≥ 90 g/L.
   2. AST、ALT ≤ 10 × ULN; Total bilirubin (TBIL) ≤ 1.5 × ULN; Serum creatinine ≤ 1.5 × ULN and Creatinine clearance ≥ 30 mL/min.
   3. Activated partial thrombin time (APTT) /Prothrombin time (PT)/International standardized ratio (INR)≤1.5 × ULN.
7. The patients with fertility agreed to use reliable contraceptive measures (such as intrauterine device [IUD], contraceptives or condoms) during the study period and within 6 months after the end of the study; The serum pregnancy test of women of childbearing age is negative within 7 days before the study enrollment.

Exclusion Criteria:

1. History of severe allergy or major hypersensitivity to paclitaxel or human serum albumin (NCI-CTCAE Version 5.0, ≥ Level 3).
2. The toxicity of previous anti-tumor treatment has not recovered (NCI-CTC AE 5.0, >Level 1); Skin reaction or other hypersensitivity caused by any reason does not return to normal.
3. Patients with active brain metastasis without treatment (including symptomatic brain metastasis or meningeal metastasis); If the brain metastasis of the patient has been treated and the condition of the metastasis is stable (the brain imaging examination at least 4 weeks before the first administration shows that the lesion is stable, and there is no new nervous system symptom, or the nervous system symptom has returned to the baseline level, and there is no need for hormone treatment at least 14 days before the first administration of the investigational treatment), and there is no evidence of new or original brain metastasis enlargement, the patient is allowed to be enrolled.
4. History of malignant tumors other than breast cancer within 5 years before the first administration, except for tumors that have recovered after treatment, such as carcinoma in situ, basal cell carcinoma, etc.

5. There are any of the following concomitant diseases:

   1. Serious or uncontrolled cardiovascular diseases: such as chronic congestive heart failure of grade Ⅱ or above (NYHA standard), uncontrolled hypertension (excluding stable ones with systolic blood pressure>150 mmHg and/or diastolic blood pressure>90 mmHg after stable treatment), etc.
   2. There are clear neurological diseases (such as epilepsy, dementia, etc.) and ≥ grade 3 peripheral neuropathy.
   3. Serious respiratory diseases, such as asthma requiring glucocorticoid drugs, chronic obstructive pulmonary disease (acute exacerbation), etc.
   4. Uncontrolled diabetes (fasting blood glucose ≥ 10 mmol/L after stable treatment).
   5. Serious chronic or active infection requiring systemic antibacterial, antifungal, or antiviral treatment (such as anti-infective drugs have been used for more than one week before the first administration and will continue to be used), including tuberculosis infection, etc.
   6. Active HBV (HBsAg positive patients need to be tested for HBV DNA, which will be excluded if the HBV DNA is greater than the upper limit of the normal value) or HCV infection (patients with polymerase chain reaction (PCR) HCV RNA within the normal value range can participate in this study) or syphilis antibody positive (and confirmed) or HIV positive.
   7. Rash on any part of the body and any disease that may cause skin reactions, such as cholestasis, systemic lupus erythematosus, eczema, allergic dermatitis, atopic dermatitis, herpes zoster, psoriasis, etc.

6. Have the following previous medical history:

   1. Major surgical operations (such as abdominal and thoracic major operations; excluding minor operations such as diagnostic puncture or infusion device implantation) have been performed within 28 days before the first administration of the study treatment, or major surgical treatment is expected to be required during the study period.
   2. Serious cardio-cerebrovascular diseases occurred within 6 months before the first administration, such as myocardial infarction, unstable angina pectoris, cerebrovascular accident (lacunar cerebral infarction without clinical significance can be included), etc.

7. The following previous/concomitant drugs or therapies exist:

   1. Those who use glucocorticoids or antihistamines or other drugs with therapeutic or preventive effects on rash within 2 weeks or 5 half-lives (whichever is longer) before the first administration.
   2. Those who need to be treated with other anti-tumor drugs during the study.
   3. Vaccinated within 4 weeks before the first administration or expected to be vaccinated during the study administration.
   4. Those who are expected to undergo radiotherapy or hemodialysis within 2 months after the first administration.
8. Patients who are pregnant, nursing or planning to become pregnant during the study.
9. Other situations in which the investigator judged that the patient was not suitable for the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: SYHX2011; Patients will be administrated with SYHX2011 once every 3 weeks.	Drug: SYHX2011; IV infusion, 260 mg/m^2
Active Comparator: Paclitaxel for injection (albumin-bound); Patients will be administrated with paclitaxel for injection (albumin-bound) once every 3 weeks.	Drug: Paclitaxel for injection (albumin-bound); IV infusion, 260 mg/m^2

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Objective Response Rate (ORR) by IRC	Up to approximately 2 years

Secondary Outcome Measures

Outcome Measure	Time Frame
Overall survival (OS)	Up to approximately 2 years
ORR by investigator	Up to approximately 2 years
Progression-Free-Survival (PFS)	Up to approximately 2 years
Time to progression (TTP)	Up to approximately 2 years
Incidence of adverse events	Up to approximately 2 years

Collaborators and Investigators

• Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Anticipated): May 1, 2023
• Primary Completion (Anticipated): September 1, 2024
• Study Completion (Anticipated): September 1, 2024

Study Registration Dates

• First Submitted: February 22, 2023
• First Submitted That Met QC Criteria: February 22, 2023
• First Posted (Estimate): March 3, 2023

Study Record Updates

• Last Update Posted (Estimate): March 3, 2023
• Last Update Submitted That Met QC Criteria: February 22, 2023
• Last Verified: February 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antineoplastic Agents, Phytogenic; Paclitaxel
• Other Study ID Numbers: SYHX2011-002

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No